Stocks and Investing
Stocks and Investing
Wed, February 3, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, February 2, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Do Kim Maintained (VRTX) at Buy with Decreased Target to $284 on, Feb 2nd, 2021
Do Kim of BMO Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $302 to $284 on, Feb 2nd, 2021.
Do has made no other calls on VRTX in the last 4 months.
There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Do's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $251 on, Tuesday, January 19th, 2021
These are the ratings of the 5 analyists that currently disagree with Do
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $288 on, Friday, November 20th, 2020
- Vincent Chen of "Bernstein" Initiated at Buy and Held Target at $275 on, Friday, November 20th, 2020
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $307 on, Friday, October 30th, 2020
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $277 on, Friday, October 30th, 2020
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020
Contributing Sources